Patent ID: 7973058

Claim:
A method for treating a migraine in a human, the method comprising: administering an anti-migraine agent in the form of a triptan compound to said human using an integrated iontophoretic transdermal patch, wherein the triptan is delivered in a delivery sequence which includes: an initial first stage delivery wherein current densities average between about 0.05 and about 0.20 mA/cm 2 during a significant portion of the initial first stage delivery such that a therapeutically effective dosage level in less than one hour is provided to the subject, wherein the therapeutically effective dosage level is a plasma concentration of greater than 10 ng/mL; and a second stage delivery wherein current densities average between about 0.01 and about 0.2 mA/cm 2 during a significant portion of said second stage delivery such that a maintenance level is provided for one or more hours, wherein said current densities of said first stage and said second stage are selected such that said current densities do not substantially irritate said human's skin.